A Study of Liposomal Doxorubicin With or Without Olaratumab (IMC-3G3) in Platinum-Refractory or Resistant Advanced Ovarian Cancer
Completed
Eli Lilly and Company
Phase 2
2009-06-01
The purpose of this study is to determine if participants with platinum-refractory or
platinum-resistant advanced ovarian cancer have a better outcome when treated with Olaratumab
(IMC-3G3) in combination with Liposomal Doxorubicin than when treated with Liposomal
Doxorubicin alone.
A Study of Paclitaxel/Carboplatin With or Without Olaratumab (IMC-3G3) in Previously Untreated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
Completed
Eli Lilly and Company
Phase 2
2010-01-01
The purpose of this study is to determine if participants with untreated locally advanced or
metastatic non-small cell lung cancer have a better outcome when treated with olaratumab in
combination with paclitaxel/carboplatin then when treated with paclitaxel/carboplatin alone.
The main purpose of this study is to gather information about the use of an investigational
drug called olaratumab with a drug for soft tissue sarcoma called doxorubicin.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
